Rosuvastatin Tablet, Film Coated
Product Images NDC 71610-922

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rosuvastatin (NDC 71610-922). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (71610 0922 45)

Label (71610 0922 45)
Label for Rosuvastatin USP 20 mg film-coated tablets, supplied in a container of 45 tablets. The label includes storage instructions, a barcode with NDC 71610-922-45, manufacturing information by ScieGen Pharmaceuticals Inc., and repackaging by Aphena Pharma Solutions - Tennessee, LLC. The product is indicated as prescription only.*
FDA Label Image

Aphena (Aphena)

Aphena (Aphena)
FDA Label Image

Figure-01 (Figure 1)

Figure-01 (Figure 1)
A line graph showing cumulative incidence percentage over approximately 6 years comparing Rosuvastatin and placebo groups. The graph includes hazard ratio (HR 0.56) with 95% confidence interval and a P-value less than 0.001. The plot shows lower incidence for Rosuvastatin compared to placebo, with a table below listing the number of patients at risk over time for each group.*
FDA Label Image

Figure-02 (Figure 2)

Figure-02 (Figure 2)
A data table presenting the number of events comparing Rosuvastatin 20 mg versus Placebo 20 mg across various cardiovascular end points. It includes columns for event rates per 1000 patient-years, hazard ratios with 95% confidence intervals, and p-values, accompanied by a graphical hazard ratio plot. End points listed are primary end point (MCE), cardiovascular death, nonfatal stroke, nonfatal MI, hospitalized unstable angina, and arterial revascularization.*
FDA Label Image

Figure-02 (Figure 3)

Figure-02 (Figure 3)
A box plot chart depicting percent change from baseline in LDL-C for four statins: Rosuvastatin, Atorvastatin, Simvastatin, and Pravastatin, across multiple doses (10, 20, 40, and 80 mg where applicable). The vertical axis ranges from 0 to -75 percent change, showing LDL-C reduction efficacy by dose and drug.*
FDA Label Image

Structural Formula (Rosuvastatin Str)

Structural Formula (Rosuvastatin Str)
Chemical structure of Rosuvastatin calcium, shown with the calcium ion indicated as Ca2+.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.